Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a ...
At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
However, healthcare is a necessity. And the healthcare sector is poised to grow over the next decade and beyond with aging populations around the world. These factors make healthcare stocks a great ...
The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...
We recently compiled a list of the Blackrock’s 30 Most Important AI Stocks. In this article, we are going to take a look at ...
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...